Post-merger, Indalo raises $9M; Spark raising $331M; No word on Shkreli’s fate
→ A St. Louis-based biotech named Indalo Therapeutics — formerly Antegrin — has picked up the first $9 million of a planned $26 million investment, according …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
